A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma

Clinical trial NCT03758417 · TERMINATED

Trial details

NCT number: NCT03758417
Sponsor: Nanjing Legend Biotech Co.
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Multiple Myeloma

Start date: 2019-01-23
Primary completion: 2025-07-10
Enrollment: 123

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.